Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2148830rdf:typepubmed:Citationlld:pubmed
pubmed-article:2148830lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:2148830lifeskim:mentionsumls-concept:C0337812lld:lifeskim
pubmed-article:2148830lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:2148830lifeskim:mentionsumls-concept:C0014582lld:lifeskim
pubmed-article:2148830lifeskim:mentionsumls-concept:C0065864lld:lifeskim
pubmed-article:2148830lifeskim:mentionsumls-concept:C0445550lld:lifeskim
pubmed-article:2148830lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:2148830lifeskim:mentionsumls-concept:C1096776lld:lifeskim
pubmed-article:2148830lifeskim:mentionsumls-concept:C0356799lld:lifeskim
pubmed-article:2148830pubmed:issue4lld:pubmed
pubmed-article:2148830pubmed:dateCreated1991-2-22lld:pubmed
pubmed-article:2148830pubmed:abstractTextA prospective randomized study has been carried out in order to compare three different treatment modalities for symptomatic metastatic hormone-resistant prostatic cancer. A total of 79 patients were included. One group was treated with estramustine phosphate, another with Epirubicin plus Medroxyprogesterone acetate (MPA), while the third arm consisted of Epirubicin plus placebo. Best palliation was obtained by the combination of Epirubicin and MPA. This combination also seemed to be associated with the longest response duration.lld:pubmed
pubmed-article:2148830pubmed:languageenglld:pubmed
pubmed-article:2148830pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2148830pubmed:citationSubsetIMlld:pubmed
pubmed-article:2148830pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2148830pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2148830pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2148830pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2148830pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2148830pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2148830pubmed:statusMEDLINElld:pubmed
pubmed-article:2148830pubmed:issn0036-5599lld:pubmed
pubmed-article:2148830pubmed:authorpubmed-author:TveterK JKJlld:pubmed
pubmed-article:2148830pubmed:authorpubmed-author:HollyFFlld:pubmed
pubmed-article:2148830pubmed:authorpubmed-author:KleppOOlld:pubmed
pubmed-article:2148830pubmed:authorpubmed-author:HagenSSlld:pubmed
pubmed-article:2148830pubmed:authorpubmed-author:SanderSSlld:pubmed
pubmed-article:2148830pubmed:authorpubmed-author:MuriOOJrlld:pubmed
pubmed-article:2148830pubmed:authorpubmed-author:UrnesTTlld:pubmed
pubmed-article:2148830pubmed:authorpubmed-author:PoulsenCClld:pubmed
pubmed-article:2148830pubmed:authorpubmed-author:SivertsenSSlld:pubmed
pubmed-article:2148830pubmed:authorpubmed-author:KlosterS ESElld:pubmed
pubmed-article:2148830pubmed:issnTypePrintlld:pubmed
pubmed-article:2148830pubmed:volume24lld:pubmed
pubmed-article:2148830pubmed:ownerNLMlld:pubmed
pubmed-article:2148830pubmed:authorsCompleteNlld:pubmed
pubmed-article:2148830pubmed:pagination243-7lld:pubmed
pubmed-article:2148830pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:meshHeadingpubmed-meshheading:2148830-...lld:pubmed
pubmed-article:2148830pubmed:year1990lld:pubmed
pubmed-article:2148830pubmed:articleTitleA randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.lld:pubmed
pubmed-article:2148830pubmed:affiliationDepartment of Urology, Ullevål Hospital, Oslo, Norway.lld:pubmed
pubmed-article:2148830pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2148830pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2148830pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:2148830pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:2148830pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2148830lld:pubmed